Yahoo
NasdaqCM - Delayed Quote USD

Aprea Therapeutics, Inc. (APRE)

0.4846 -0.0090 (-1.82%)
At close: October 30 at 4:00:01 PM EDT
Chart Range Bar
Loading chart for APRE
  • Previous Close 0.4936
  • Open 0.4788
  • Bid 0.7847 x 200
  • Ask 0.8594 x 200
  • Day's Range 0.4600 - 0.5214
  • 52 Week Range 0.4100 - 1.4900
  • Volume 167,609
  • Avg. Volume 310,114
  • Market Cap (intraday) 6.102M
  • Beta (5Y Monthly) 1.63
  • PE Ratio (TTM) --
  • EPS (TTM) -0.9500
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 3.30
  • Zacks Rating Neutral

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

aprea.com

8

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

APRE
43.19%
S&P 500 (^GSPC)
10.73%

1-Year Return

APRE
66.58%
S&P 500 (^GSPC)
11.11%

3-Year Return

APRE
86.44%
S&P 500 (^GSPC)
81.91%

5-Year Return

APRE
99.51%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -3.29M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-3M
-2M
-1M
0
-150000.0%
-100000.0%
-50000.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

1.20
3.30 Average
0.4846 Current
5.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/14/2026
Analyst Ladenburg Thalmann
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 2

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -27.73%

  • Return on Equity (ttm)

    -46.15%

  • Revenue (ttm)

    5.18k

  • Net Income Avi to Common (ttm)

    -12.31M

  • Diluted EPS (ttm)

    -0.9500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    41.23M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -8.15M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: